Mammadov Elnur, Aslan Guven, Tuna Burcin, Bozkurt Ozan, Yorukoglu Kutsal
Urology, Medicine, Dokuz Eylul University , Izmir, Turkey E-mail :
Asian Pac J Cancer Prev. 2014;15(23):10401-5. doi: 10.7314/apjcp.2014.15.23.10401.
Molecular prognostic markers have been under investigation for the last decade and no validated marker to date has been proven to be used in daily clinical practice for urinary bladder cancers. The aim of the present study is to evaluate the significance of HYAL-1 expression in prediction of recurrence and progression in pT1 urothelial carcinomas.
Eighty-nine urothelial carcinoma cases staged as T1 according to 2004 WHO classification were studied. Representative sections from every case were stained immunohistochemically for HYAL-1 and scored between 0 and +3, according to staining density, and graded as low and high for the scores 0-1 and 2-3, respectively.
Of the 89 pT1 bladder cancer patients, HYAL-1 expression was high in 92.1% (82 patients; 72 patients +3 and 10 patients +2) and low in 7.9% (only 7 patients; 6 patients +1 and 1 patient 0) of the cases. Of the 89 patients, 38 (42.7%) had recurrence and 22 (24.7%) showed progression. HYAL-1 staining did not show significant characteristics for tumor grade, accompanying CIS, multiplicity, tumor size, age and sex. HYAL-1 expression did not have any prognostic value in estimating recurrence or progression.
HYAL-1 expression was found to be high, but did not have any prognostic importance in T1 bladder urothelial carcinomas.
